CITY OF ST. JOSEPH HEALTH DEPARTMENT

Public Health
Prevent. Promote. Protect.

COVID-19 Briefing

March 7, 2022

VACCINATION Locations for COVID-19 Buchanan County

The City of St. Joseph Health Department does not have specifics on the vaccination process at these locations. Please visit their websites or call for more details. For corrections or additions call 816.236.1491

City of St. Joseph Health Department

Health Department Clinic
904 S. 10th St, Suite B, St. Joseph, MO
Monday – Friday, 8:00am
11:00am and 1:00pm – 4:00pm
1st, 2nd, 3rd, Booster Doses
Pfizer vaccine for ages 5 and older

Mosaic Life Care

Patients that are established with a Mosaic Provider (primary or specialty) can contact the provider to schedule an appointment.

Non-Mosaic Providers for Children Ages 5 and Up

Peacock Pediatrics – Children Ages 5+
805 N. 36th St, Suite B, St. Joseph 64506
(816) 396-6026

Downing Pediatrics – Children Ages 5+
3839 Frederick Ave, St. Joseph, 64506
(816) 396-8855

Pharmacies

Sam's Club - 1st, 2nd, 3rd, Booster Doses – Ages 5+
Moderna - 5201 N Belt Hwy, St Joseph, MO 64506
https://samsclub.com/covid

Walgreens - 1st, 2nd, 3rd, Booster Doses – Ages 5+
Pfizer - 4022 N Belt Hwy, St Joseph 64506
Pfizer - 3645 Frederick Ave, St Joseph 64506
Pfizer - 2620 S Belt Hwy, St Joseph 64503
https://www.walgreens.com/covid

Walmart - 1st, 2nd, 3rd, Booster Doses – Ages 5+
Moderna & Pfizer - 4201 N Belt Hwy, St Joseph MO 64506
Moderna & Pfizer - 3022 S Belt Hwy St Joseph MO 64503
https://www.walmart.com/COVIDvaccine

CVS – 1st, 2nd, 3rd, Booster Doses – Ages 12+
Moderna - 5201 N Belt Hwy (Target) , St Joseph, MO 64506
Pfizer - 3320 N Belt Hwy, St Joseph, MO 64506
Pfizer - 930 N Belt Hwy, St Joseph, MO 64506
Moderna - 1301 S Belt Hwy, St Joseph, MO 64507
https://www.cvs.com/coronavirus

Hy-Vee - 1st, 2nd, 3rd, Booster Doses – Ages 12+
Pfizer - 201 N Belt Hwy, St Joseph, MO 64506
https://www.hy-vee.com/my-pharmacy/covid-vaccine

Rogers - 1st, 2nd, 3rd, Booster Doses – Ages 16+
Moderna & J&J - N Belt Hwy, St Joseph, MO 64506
(816) 232-3348—Choose option 10 to register

Additional Primary Shot for Certain Immunocompromised Persons

After completing the primary series, some moderately or severely immunocompromised people should get an additional primary shot. A full list of moderately or severely Immunocompromised conditions can be found on CDC's website.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html

Booster Dose Information

Everyone Ages 12 and Older Can Get a Booster Shot. If you are 18 years or older you may choose which COVID-19 vaccine you receive as a booster shot. Some people may prefer the vaccine type that they originally received, and others may prefer to get a different booster. CDC's recommendations now allow for this type of mix and match dosing for booster shots.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html?s_cid=11705:who%20is%20eligible%20for%20covid%20booster:sem.ga:p:RG:GM:gen:PTN:FY22

mRNA Vaccine Preference

CDC has updated its recommendations for COVID-19 vaccines with a preference for people to receive an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna). Read CDC's media statement.

https://www.cdc.gov/media/releases/2021/s1216-covid-19-vaccines.html

CDC WE CAN DO THIS

3/7/2022

Find a COVID-19 Vaccine at a Providers office or a Location Near You

www.vaccines.gov ~ 1-800-232-0233 ~ TTY 1-888-720-7489 ~Disability Info/Access Line 1-888-677-1199

TESTING Locations for COVID-19 in Buchanan County

The City of St. Joseph Health Department does not have specifics on the testing process at these locations. Please visit their websites or call for more details. For corrections or additions call 816.236.1491

MOSAIC COVID-19 TESTING HOTLINE 1-855-577-0211
For help finding a testing location near you.

Pharmacies (By Appointment)

CVS
3320 N Belt Hwy, St. Joseph 64506
930 N Belt Hwy, St. Joseph 64506
1301 S Belt Hwy, St. Joseph 64507
https://www.cvs.com/minuteclinic/covid-19-testing

Hy-Vee
201 N Belt Hwy, St. Joseph 64506
https://www.hy-vee.com/my-pharmacy/services/covid-19-testing

Walgreens
4022 N Belt Hwy, St. Joseph 64506
3645 Frederick Ave, St. Joseph 64506
2620 S Belt Hwy, St. Joseph 64503
https://www.walgreens.com/findcare/covid19/testing

Urgent Care (Walk-in or "Hold My Spot")

Mosaic Life Care Urgent Care
**Use your Mosaic portal to "Hold My Spot"*
1115 N Belt Hwy St. Joseph 64506
(816) 271-7077

Urgent Care Express
** Not a Medicaid Provider*
4776 Verona Dr, St. Joseph 64506
(816) 396-9500

Laboratories

AEL Eastridge
Testing is FREE, Walk-in
Dr.'s orders and Insurance NOT REQUIRED
212 South Woodbine, St. Joseph 64506
(816) 233-9313

River City Laboratory
Walk-in, Doctor's Ordered Required,
Insurance OR $100 cash payment
212 South Woodbine, St. Joseph 64506
(816) 306-8108

Quest Diagnostic
Not accepting people with active COVID-19 symptoms
Appointment needed, walk-ins not guaranteed test
Must have Dr.'s orders or pay for test
https://appointment.questdiagnostics.com/as-home
1213 N Belt Hwy Ste C, St Joseph 64506
(816) 233-1039

FREE State-wide Testing Sites
PCR Testing events scheduled state-wide, some recurring weekly. Most are drive-thru.
If indoors, it will be clearly stated.
www.health.mo.gov/communitytest
1-877-435-8411

Medical Providers (By Appointment)

Advanced Dermatology & Skin Cancer Center
New and established patients
1427 Village Dr., St. Joseph, MO 64506
(816) 364-1515

Downing Pediatrics
For established patients
805 N 36th St Suite B, St. Joseph 64506
(816) 396-8855

Mosaic Providers
For established patients
Various Locations – Call your provider directly

NW Health Services Providers
For established patients
All locations
www.nwhealth-services.org/locations
(816) 271-8261

Peacock Pediatrics
For established patients
3839 Frederick Ave., St. Joseph 64506
(816) 396-6026

St. Joseph VA Clinic
Dr.'s order required, Restrictions apply
3302 South Belt Highway, Suite P, St. Joseph 64503
(816) 676-1044

3/7/2022

FREE At-Home COVID-19 Test Kit Options

For Insured Persons Rapid Antigen At-Home test kits at Retailers and Pharmacies (Get it for **FREE** or be Reimbursed)

How to get your At-Home Over-The-Counter COVID-19 Test for Free

https://www.cms.gov/how-to-get-your-at-home-OTC-COVID-19-test-for-free

Starting January 15, most people with a health plan can go to a pharmacy, store or online to purchase an at-home over-the-counter COVID-19 test **AT NO COST**, either through reimbursement or free of charge through their insurance.

- The test will either be free at the pharmacist counter, if your health plan provides for direct coverage, or by reimbursement if you are charged for your test. Pharmacy staff may be able to check your insurance plan to see what the coverage options are. Please have insurance card available if needed.
- If you are charged for your test after January 15, keep your receipt and submit a claim to your insurance company for reimbursement.
- Private insurance companies are required to reimburse up to 8 tests per month per individual on an insurance plan, regardless of whether the tests are bought all at once or at separate times throughout the month.

FREE Rapid Antigen At-Home test kits shipped to home

(sponsored by US DHHS & USPS)

The U.S. Dept of Health and Senior Services has partnered with the U.S. Postal Service to ensure residential households in the U.S. can get one set of four (4) free at-home tests from USPS.com.

- Every home in the U.S. is eligible to order 4 free at-home COVID-19 tests. The tests are completely free.
- Orders will usually ship in 7-12 days.
- **Order your tests now so you have them when you need them**.

Here's what you need to know about your order:

- Limit of one order per residential address
- One order includes four (4) individual rapid antigen COVID-19 tests.
- Orders will ship free starting in late January

Order your test kit here

https://www.covidtests.gov/

If you need a COVID-19 test now, please utilize other testing options in your area.

FREE PCR At-Home test kits shipped to home

(sponsored by Missouri DHSS)

This option allows for ordering a kit to be shipped to your home. Once ordered, the kit typically arrives in 2 days (depending on current demand).

- After self-collection by easy-to-follow instructions, the kit is shipped free of charge via FedEx in the prepaid FedEx shipping envelope (according to directions) and returned to a FedEx collection site within 24 hours where it will be sent to a laboratory
- You must provide an email address in order to receive the test result.
- The kit is good for 6 months.
- **Order your tests now so you have them when you need them.**

Please note that due to the current spike in demand, a limited quantity will be available each day through January. If the ordering site says the limit has been reached, please check back again the following day for availability. Thank you for your patience.

Order your test kit here

https://picturegenetics.com/covid19?c=MOPROMO

The Picture Support Hotline can be reached at 626-434-3596. This team can help navigate through any ordering, activation, shipping and/or troubleshooting issues with the Picture Portal platform.

Resources to learn more about the self-collection test:

- English detailed instructions: https://www.youtube.com/watch?v=X7iMymqodi8
- Spanish detailed instructions https://www.youtube.com/watch?v=qkLMaVaEk40
- Visit fedex.com/dropbox to check on nearest dropbox and pickup times.
- How to Schedule a Fed-Ex Pick-up if dropbox not available near you https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/pdf/how-to-schedule-fedex-pick-up.pdf

If you need a COVID-19 test now, please utilize other testing options in your area.

- **If you test positive**, you should isolate and inform your healthcare provider, as well as any close contacts.
- A positive self-test result means that the test detected the virus, and you are very likely to have an infection. You should stay home and isolate from other people for at least 5 full days (day 0 is the first day of symptoms or the date of the day of the positive viral test for asymptomatic persons). You should wear a mask when around others at home and in public for an additional 5 days (Days 6-10) and avoid indoor gatherings to reduce the risk of spreading disease to someone else.
- A negative self-test result means that the test did not detect the virus and you may not have an infection, but it does not rule out infection. Repeating the test within a few days, with at least 24 hours between tests, will increase the confidence that you are not infected.
- Learn More: https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html#isolation

3/7/2022

COVID-19 VACCINE DASHBOARD

** Fluctuations in vaccination counts may occur as the State continues to review records for completeness and accuracy **

County Name	Number of people who have initiated vaccination	Percent of population initiating vaccination	Number of people who have completed vaccination	Percent of population completing vaccination	Total COVID-19 Doses Administered	7-Day Doses Administered	7-Day Avg Doses Administered
Buchanan	34,586	39.6%	32,463	37.2%	76,736	185	26



https://covidvaccine.mo.gov/data/#county_data



https://covidvaccine.mo.gov/data/#statewide_data

3/7/2022

BUCHANAN COUNTY TESTING POSITIVITY RATE

7 Day Percent of Positive PCR & Antigen Tested Individuals

5.07%

Number of Persons Tested via PCR or Antigen Tests

1,340

MISSOURI TESTING POSITIVITY RATE

Positivity Rate Over the Last 7 Days (PCR Only CDC Method)

4.5%

Positivity Rate Over the Last 7 Days (Antigen Only)

2.2%

US TESTING POSITIVITY RATE

7 Day Percent Positive of PCR Tested Individuals (as of 12/27/21)

3.24%

https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/data/public-health/testing.php
https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/data/public-health/
https://covid.cdc.gov/covid-data-tracker/#cases_testsper100k7day

BUCHANAN COUNTY TESTING POSITIVITY RATE (PCR & Antigen Tests)



COVID-19 IN BUCHANAN COUNTY

	Total Cases	Confirmed Cases	Probable Cases	Hospitalizations	Deaths	Positivity Rate
Total Count	24,640	17,504	7,136	11	253	5.07%
Change Since Last Report	+37	+30	+7	-5	0	-2.94%

Confirmed case: The case meets the confirmed laboratory evidence, which is the detection of SARS-CoV-2 RNA in a clinical specimen using an approved detection test verified by a certified testing laboratory.

Probable case: The case meets clinical criteria AND epidemiologic evidence (close contact with a confirmed or probable case; travel to or residence in an area with sustained, ongoing community spread; or a member of a risk cohort as defined by public health authorities during an outbreak), with no confirmatory laboratory testing performed for COVID-19.

Positivity Rate - The 7-day positivity rate is based on PCR and Antigen testing rates for Buchanan County residents and will be updated once a week on Mondays.

Currently Hospitalized – Mosaic Daily Inpatient Update: COVID-19 patient count is minimal. If the Mosaic system has more than ten COVID-19 inpatients, their website will be updated https://www.mymlc.com/General/coronavirus-covid-19/#DailyInpatientUpdate. Patients may not be Buchanan County residents.

3/7/2022

BUCHANAN COUNTY COVID-19 CASE DEMOGRAPHICS







BUCHANAN COUNTY 14-DAY TREND

This is the number of new cases over the past 14 days.

The straight line shows the trend of new cases.

3/7/2022

COVID-19 IN MISSOURI

Missouri COVID-19 Dashboard will provide COVID-19 data for state and county levels:

MO DHSS numbers have continued to fluctuate as the state makes adjustments to ensure COVID-19 cases are not counted twice. This could occur if a person received a positive antigen test followed up with a confirmatory PCR test – initially some people who fall into that category were counted in both. In order to report accurately, the state regularly reviews positive tests and corrects the numbers.

Statewide as of March 7, 2022
New Cases Last 24 Hours: + 450
Total Cases: 1,400,761
Total Deaths: 19,088
Persons Completing Vaccination: 3,451,997

COVID-19 in Missouri

NOTE on dates: This dashboard was last updated in the afternoon of **3/7/2022** and includes data reported through **3/6/2022**. All 7-day metrics are based on the date a test or death *occurred*, and are subject to a 3-day delay to ensure data are accurate and complete. See FAQ for details.
Range for 7-Day metrics: 2/26/2022 through 3/4/2022

COVID-19 in Missouri to Date

Confirmed Cases to Date	1,125,901	
Probable Cases to Date	274,860	
Confirmed Deaths to Date	15,415	
Probable Deaths to Date	3,673	
PCR Tests to Date	9,679,987	
Antigen Tests to Date	4,402,794	

COVID-19 in Missouri - Past 7 Days (based on date of occurrence)

		3/4	3/3	3/2	3/1	2/28	2/27	2/26
Confirmed Cases: Past 7 Days	2,203 (daily avg. of 315)	234	313	309	348	472	267	260
Probable Cases: Past 7 Days	477 (daily avg. of 68)	47	60	79	67	107	60	57
Confirmed Deaths: Past 7 Days	4 (see note)	0	3	0	1	0		
Probable Deaths: Past 7 Days	1 (see note)	0	0	1	0	0		
PCR Tests: Past 7 Days	56,870 (total daily avg. of 8,124)	6,640	8,136	8,616	10,264	14,556	4,155	4,503
Antigen Tests: Past 7 Days	29,427 (total daily avg. of 4,204)	2,434	4,755	4,780	4,493	6,776	4,302	1,887

https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/data/public-health/statewide.php

3/7/2022

CASES AND DEATHS IN VACCINATED MISSOURIANS

What is a breakthrough infection? A breakthrough infection is a COVID-19 case that occurs in someone who is fully vaccinated, meaning 14 or more days after completing the recommended doses of an authorized vaccine.

This dashboard was last updated on 3/7/2022, with the most recent testing data (3/6/2022), vaccine data (3/7/2022), and breakthrough data (3/4/2022). All metrics below include **reported** cases and deaths since 1/1/2021.

Fully Vaccinated Missourians: **3,451,997**

Cases	Deaths
Percent of **fully vaccinated** people who developed infection (among all vaccinated persons): **8.01%** (Total Breakthrough Cases: **276,368** / Total Fully Vaccinated People: **3,451,997**)	Percent of **fully vaccinated** people who died of COVID-19 (among all vaccinated persons): **0.05%** (Total Breakthrough Deaths: **1,606** / Total Fully Vaccinated People: **3,451,997**)
Percent of cases in **unvaccinated or partially vaccinated** people (among all COVID-19 cases): **71%** (Total Cases Non-Fully Vaccinated: **666,655** / Total Cases: **943,023**)	Percent of deaths in **unvaccinated or partially vaccinated** people (among all COVID-19 deaths): **85%** (Total Deaths Non-Fully Vaccinated: **9,130** / Total Deaths: **10,736**)

https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/data/public-health/health-metrics/breakthrough-cases.php



REINFECTION CASES
IN MISSOURIANS

What is a reinfection? A reinfection case occurs when someone tested positive for COVID-19 via a PCR or Antigen test, recovers, then 90 days or later tested positive again via a PCR or Antigen test.


This dashboard was last updated on 3/7/2022 and reflects all reported testing and death data through 3/6/2022. All metrics below include reported cases and deaths.

Total COVID-19 Cases in Missouri*: 929,033

* Note: Counts reflect cumulative cases as of 90 days ago to allow cases to be capable of becoming a reinfection.

Percent of **previously infected** people who developed a reinfection:
4.51%
(Total Reinfection Cases: 41,931 / Total Previously Infected Cases*: 929,033)

Percent of **previously infected** people who died of a reinfection:
0.02%
(Total Reinfection Deaths: 158 / Total Previously Infected Cases*: 929,033)

https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/data/public-health/health-metrics/reinfections.php



COVID-19 IN THE US AND WORLDWIDE

Worldwide as of March 7, 2022

New Cases Last 24 Hours: +1,200,707
Total Cases: 445,096,612
Total Deaths: 5,969,439
Persons Completing Vaccination: 4,377,548,164



United States as of March 7, 2022

New Cases Last 24 Hours: +6,174
Total Cases: 79,094,974
Total Deaths: 955,958
Persons Completing Vaccination: 216,204,455



* Source: World Health Organization https://covid19.who.int/

Note: You likely notice a difference in the case counts if you are following other organizations, such as Johns Hopkins. The CDC updates case totals each day, reporting the cases numbers from the previous day. Other sites use sources for real time counts.

* Source: Center for Disease Control and Prevention
https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days
https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total

Monoclonal Antibody (mAb) Infusion Center

Have you tested positive for COVID or think you may have it?



Good news! There is a treatment available that may reduce your risk of developing serious symptoms or winding up in the hospital.

Depending on your age, health history, and how long you've had symptoms of COVID-19, you may qualify for a promising form of treatment for the disease. It's called monoclonal antibody (mAb) treatment. The key is receiving this treatment within 10 days of contracting COVID-19, so don't wait to see how bad your case will be!

Monoclonal antibody (mAb) treatment may also be administered to exposed close contacts who are at high risk for developing severe COVID-19 illness.

Talk to your doctor about a referral.

There is one location in our region currently offering mAb therapy:

- **St. Joseph** - Mosaic Life Care, 5325 Faraon, St. Joseph, MO. Call your primary care provider to see if you qualify for the infusion. Don't have a primary care provider? Call 816-271-6646.

To learn more about the monoclonal antibody infusion, visit https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients

3/7/2022

Full report dated March 4, 2022: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

In Focus: COVID-19 Community Levels

Last week CDC launched COVID-19 Community Levels, a new tool for helping people and communities decide on prevention steps based on the latest data. There are three levels (low, medium, high), which are determined by looking at hospital beds being used by patients with COVID-19, new hospital admissions among people with COVID-19, and the total number of new COVID-19 cases in your area. It's easy to check your county's level on CDC's website and find out what actions you should take.

The whole community can be safe only when we all take steps to protect each other, even when the COVID-19 Community Level is low or medium. No matter what your COVID-19 Community Level, layered prevention strategies can help limit severe disease and reduce the potential for strain on the healthcare system. Proven prevention steps include staying up to date on vaccines, getting tested if you have symptoms, and wearing a mask when you're around someone at increased risk for severe COVID-19. For more information on the science behind the levels and how CDC measures them, see our A Closer Look section.

Low	Medium	High
• Stay up to date with COVID-19 vaccines • Get tested if you have symptoms	• If you are at high risk for severe illness, talk to your healthcare provider about whether you need to wear a mask and take other precautions • Stay up to date with COVID-19 vaccines • Get tested if you have symptoms	• Wear a mask indoors in public • Stay up to date with COVID-19 vaccines • Get tested if you have symptoms • Additional precautions may be needed for people at high risk for severe illness
People may choose to mask at any time. People with symptoms, a positive test, or exposure to someone with COVID-19 should wear a mask.		

INFORMATION FOR HEALTH CARE PROFESSIONALS

Morbidity and Mortality Weekly Report (MMWR) March 4, 2022 / No. 9

https://www.cdc.gov/mmwr/index2022.html

Pdf of this issue https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7109-H.pdf

SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022

Summary

What is already known about this topic?

The SARS-CoV-2 B.1.1.529 (Omicron) variant contributed to a surge of SARS-CoV-2 infections in the United States during December 2021–January 2022.

What is added by this report?

In a study of household transmission in four U.S. jurisdictions, Omicron infection resulted in high transmission among household contacts, particularly among those who lived with index patients who were not vaccinated or who did not take measures to reduce the risk of transmission to household contacts.

What are the implications for public health practice?

Multicomponent COVID-19 prevention strategies, including up-to-date vaccination, isolation of infected persons, and mask use at home, are important to reduce Omicron transmission in household settings.



COVID-19 Related articles:

- **Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties — United States, December 14, 2020–January 31, 2022** https://www.cdc.gov/mmwr/volumes/71/wr/mm7109a2.htm?s_cid=mm7109a2_w
- **SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022** https://www.cdc.gov/mmwr/volumes/71/wr/mm7109e1.htm?s_cid=mm7109e1_w
- **Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022** https://www.cdc.gov/mmwr/volumes/71/wr/mm7109e2.htm?s_cid=mm7109e2_w
- **Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022** https://www.cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w

INFORMATION FOR HEALTH CARE PROFESSIONALS

FDA Roundup: March 1 and 4, 2022

https://www.fda.gov/news-events/press-announcements/fda-roundup-march-4-2022
https://www.fda.gov/news-events/press-announcements/fda-roundup-march-1-2022

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

- Today, the FDA issued a safety communication warning people not to use the Celltrion DiaTrust COVID-19 Ag Rapid Test that is in green and white packaging. The test has not been authorized, cleared or approved by the FDA for distribution or use in the United States. The FDA is concerned about the risk of false results when using this unauthorized test.
- Today, the FDA issued a safety communication warning people not to use the SD Biosensor STANDARD Q COVID-19 Ag Home Test. This test is packaged in a white and magenta box and has not been authorized, cleared or approved by the FDA for distribution or use in the United States. The FDA is concerned about the risk of false results when using this unauthorized test.
- Today, the FDA issued a safety communication warning people not to use the ACON Laboratories “Flowflex SARS-CoV-2 Antigen Rapid Test (Self-Testing).” This test is packaged in a dark blue box and has not been authorized, cleared or approved by the FDA for distribution or use in the United States. The FDA is concerned about the risk of false results when using this unauthorized test.

COVID-19 testing updates:

- As of today, 419 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 290 molecular tests and sample collection devices, 85 antibody and other immune response tests and 44 antigen tests. There are 70 molecular authorizations and 1 antibody authorization that can be used with home-collected samples. There is 1 EUA for a molecular prescription at-home test, 2 EUAs for antigen prescription at-home tests, 14 EUAs for antigen over-the-counter (OTC) at-home tests, and 3 for molecular OTC at-home tests.
- The FDA has authorized 25 antigen tests and 9 molecular tests for serial screening programs. The FDA has also authorized 859 revisions to EUA authorizations.

INFORMATION FOR HEALTH CARE PROFESSIONALS

NIH COVID-19 Treatment Guidelines Update - March 2, 2022

https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/

March 2, 2022

The COVID-19 Treatment Guidelines Panel's Statement on the Role of Bebtelovimab for the Treatment of High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19

On February 11, 2022, the Food and Drug Administration issued an Emergency Use Authorization (EUA) for the anti-SARS-CoV-2 monoclonal antibody (mAb) bebtelovimab for the treatment of nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease. The issuance of this EUA was primarily based on in vitro antiviral data showing that bebtelovimab is expected to have activity against a broad range of SARS-CoV-2 variants, including the B.1.1.529 (Omicron) variant of concern and its BA.1 and BA.2 subvariants.

Clinical trial data for bebtelovimab are limited to a Phase 2, randomized, placebo-controlled trial in patients who were at low risk for progression to severe disease. The trial showed no unexpected safety events, and patients who received bebtelovimab had more rapid viral decay than those who received the placebo. Although there are insufficient data on hospitalization and mortality outcomes for patients at high risk of disease progression who have received bebtelovimab, the agent has a mechanism of action similar to other anti-SARS-CoV-2 mAbs that have been shown in Phase 3 trials to reduce hospitalization or death among high-risk patients.

The purpose of this statement is to provide clinicians with guidance on the role of bebtelovimab as an additional treatment option for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease. Basing its recommendations on collective in vitro data, clinical trial results, and other factors (e.g., drug interaction potential, feasibility), the Panel has classified the 5 available treatment options as preferred or alternative therapies for use in this population. Phase 3 trials have demonstrated high efficacy for the preferred therapies. The Panel recommends 1 of the following:

Preferred therapies (listed in order of preference):

- **Nirmatrelvir 300 mg with ritonavir 100 mg (Paxlovid) (AIIa)**; *or*
- **Sotrovimab 500 mg (AIIa)**; *or*
- **Remdesivir 200 mg (BIIa)**

Alternative therapies (for use if none of the preferred therapies are available, feasible to deliver, or clinically appropriate, listed in alphabetical order):

- **Bebtelovimab 175 mg (CIII)**; *or*
- **Molnupiravir 800 mg (CIIa)**

The statement has detailed information regarding dose, route of administration, duration of therapy, and other specific indications.

INFORMATION FOR HEALTH CARE PROFESSIONALS

NIH COVID-19 Treatment Guidelines Update - February 24, 2022

https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/

February 24, 2022

Therapeutic Management of Hospitalized Adults With COVID-19

The figure and text in this section have been updated to incorporate the information and recommendations from the Panel's statement on using therapeutic or prophylactic anticoagulation in hospitalized adults with COVID-19.

Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children (MIS-C) (With Discussion on Multisystem Inflammatory Syndrome in Adults [MIS-A])

In this new section, the Panel provides recommendations for the treatment of children with multisystem inflammatory syndrome in children (MIS-C). The Panel notes that there are no randomized controlled trials that compare treatment approaches for MIS-C. However, data from large descriptive and observational comparative effectiveness studies are available to guide treatment for MIS-C. Based on the available data, the Panel recommends that initial therapy for MIS-C include a combination of immunomodulatory therapy (i.e., intravenous immunoglobulin plus a low to moderate dose of a glucocorticoid) and antithrombotic therapy.

Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19

This page has been updated to include recommendations for using ritonavir-boosted nirmatrelvir (Paxlovid), remdesivir, and molnupiravir in nonhospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression. The Panel has also clarified that the page specifically addresses recommendations for small-molecule antiviral drugs.

Ritonavir-Boosted Nirmatrelvir (Paxlovid)

This new section consolidates information from the Panel's statements on therapies for high-risk, nonhospitalized patients and potential drug-drug interactions between ritonavir-boosted nirmatrelvir and concomitant medications, which were released in December 2021. The drug-drug interaction table has been expanded to include medications that require dose adjustments when coadministered with ritonavir-boosted nirmatrelvir.

Remdesivir

This section now includes the Panel's recommendation for using remdesivir in nonhospitalized patients with mild to moderate COVID-19 and a high risk of disease progression. The PINETREE trial for outpatient therapy has also been added to the clinical data table.

Molnupiravir

This new section incorporates information from the Panel's statement on therapies for high-risk, nonhospitalized patients, which was released in December 2021.

Table 2f. Characteristics of Antiviral Agents

Ritonavir-boosted nirmatrelvir and molnupiravir have been added to this table. The remdesivir entry has also been updated to incorporate recent Food and Drug Administration labeling changes, and the Panel has clarified that this table specifically discusses small-molecule antiviral drugs.

Antithrombotic Therapy in Patients With COVID-19

This section has been updated to incorporate the information and recommendations from the Panel's statement on using therapeutic or prophylactic anticoagulation in hospitalized adults with COVID-19. A new clinical data table has been created to describe the study designs and results from the randomized controlled trials that had the greatest impact on the Panel's recommendations.

INFORMATION FOR HEALTH CARE PROFESSIONALS

Missouri Department of Health and Senior Services – Health Care Professionals
https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/professionals.php#collapseTwo

Centers for Disease Control and Prevention (CDC) - Healthcare Workers: Information on COVID-19
https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

National Institutes of Health - Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
https://www.covid19treatmentguidelines.nih.gov/

U.S. Food & Drug Administration – COVID-19
https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19

U.S. Department of Health and Human Services – COVID-19
https://www.hhs.gov/coronavirus/index.html

SOURCES OF INFORMATION

Missouri Department of Health and Senior Services
https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/

Center for Disease Control and Prevention
https://www.cdc.gov/coronavirus/2019-ncov/index.html

World Health Organization
https://covid19.who.int/